ACOR

Acorda Therapeutics
ACOR

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

29 hedge funds and large institutions have $3.71M invested in Acorda Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

less capital invested

Capital invested by funds: $ → $

less funds holding

Funds holding: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
29
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$21K
Puts
$19K
Net Calls
Net Calls Change

Top Buyers

1
+$115K
2
+$9.61K
3
+$7.62K
4
HF
HRT Financial
New York
+$7K
5
TRCT
Tower Research Capital (TRC)
New York
+$3.66K

Top Sellers

1
-$332K
2
-$26.7K
3
-$24.1K
4
UAS
United Asset Strategies
New York
-$20.8K
5
Millennium Management
Millennium Management
New York
-$13.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$3.52K
27
$29
28
–
29
–
30
–
31
–
32
–
33
–
1
2